Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest Multiple myeloma Stories

2013-11-19 08:28:41

Findings Highlight Company's Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab RARITAN, N.J., Nov. 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen compounds have been selected for presentation at the 55(th) American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. Nine pieces of company-sponsored research will be presented out of a total of nearly 50 abstracts involving...

2013-11-19 08:27:29

- Results published in Clinical Cancer Research - JERUSALEM, Nov. 19, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today the publication of results showing that BL-8040 (formerly known as BKT-140) enables the efficient mobilization of stem cells from the bone marrow into the peripheral blood, thus facilitating autologous stem cell transplantation in multiple myeloma patients. The research was published in the journal,...

2013-11-07 16:32:23

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55(th) American Society of Hematology (ASH) Annual Meeting and Exposition on...

2013-10-01 23:03:17

In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd. London,UK (PRWEB) October 01, 2013 Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib)...

2013-09-23 12:26:26

MUMBAI, India, September 23, 2013 /PRNewswire/ -- Bharat Book Bureau presents Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A [http://www.bharatbook.com/healthcare-market-research-reports/treating-refractory-hematological-malignancies-multiple-myeloma-mmnew-treatment-options-driving-in-licensing-and-m-a.html ] The report provides an overview of the therapies for Multiple Myeloma (Newly...

2013-09-22 23:01:05

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A is the new research report added to ReportsnReports.com store. Dallas, TX (PRWEB) September 22, 2013 The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the...

2013-09-18 15:26:41

Findings provide insights for new, targeted cancer therapies in clinical trials Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. Working in collaboration with colleagues at Princess Margaret Hospital in Toronto, researchers from Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) in Phoenix were...

2013-09-13 16:24:03

New survey shows majority of Canadians participate in local fundraising events such as walks MONTREAL, Sept. 13, 2013 /CNW/ - This September, ten cities across Canada will take part in the 5(th) annual Multiple Myeloma March, a national fundraising event that supports multiple myeloma research, advancements in treatment and much-needed patient and caregiver programs in communities across Canada. Driven by patients and their friends and families, the Multiple Myeloma March is...

2013-08-20 08:31:08

STOCKHOLM, August 20, 2013 /PRNewswire/ -- Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1). (Logo: http://photos.prnewswire.com/prnh/20130521/613959 ) The trial is an open-label Phase II study designed to determine the level of efficacy of melflufen in combination with...

2013-08-19 13:11:48

A gene that helps control the aging process by acting as a cell's internal clock has been linked to cancer by a major new study. Scientists at The Institute of Cancer Research, London, found a genetic variant that influences the aging process among four new variants they linked to myeloma – one of the most common types of blood cancer. The study more than doubles the number of genetic variants linked to myeloma, bringing the total number to seven, and sheds important new light on the...